On July 30, 2026, the Paris Local Division of the Unified Patent Court ruled on a preliminary objection filed by Viatris Santé amidst an infringement action by Merz against Viatris. Viatris sought to stay proceedings and redirect jurisdiction to the Tribunal Judiciaire de Paris, invoking Articles of the Brussels I recast Regulation and UPC Rules of Procedure. Merz argued against lis pendens, stating the UPC was seized first, and claimed exclusive jurisdiction. Merz also contended the criteria for related actions, like risk of irreconcilable judgments, were unmet. The case centered around French SPC No. 13C0033 and the EP No. 2 377 536 patent related to the drug FAMPRIDINE VIATRIS LP 10 mg. The court maintained its proceedings.